Diagnostic Usefulness of Cytomegalovirus (CMV)-Specific T Cell Immunity in Predicting CMV Infection after Kidney Transplantation: A Pilot Proof-of-Concept Study

Background Cytomegalovirus (CMV) is one of the most important opportunistic infections in transplant recipients. Currently sero-positivity for CMV IgG before solid organ transplantation is the laboratory test of choice for stratifying the risk of CMV reactivation after solid organ transplantation. Theoretically, CMV-specific cell-mediated immune responses before solid organ transplantation should further categorize patients as high or low risk of CMV development. We therefore evaluated the usefulness of the CMV-specific enzyme-linked immunospot (ELISPOT) assay in kidney transplant (KT) candidates for predicting the development of CMV infections after transplantation. Materials and Methods All adult CMV IgG (+) recipients admitted to the KT institute between March 2014 and June 2014 were enrolled, and CMV infections after KT were observed between March 2014 and December 2014. All patients underwent CMV pp65 and IE1-specific ELISPOT assays before transplantation. CMV infection was defined in the presence of CMV antigenemia, CMV syndrome, or tissue-invasive CMV disease. We used the data to select optimal cut-off values for pp65 and IE1, respectively, on ROC curves. Results A total of 69 transplant recipients involving 54 (78%) living-donor KT, 9 (13%) deceased-donor KT, 3 (4%) kidney-pancreas transplants, and 3 (4%) pancreas transplants were enrolled. Of the 69 patients, 27 (39%) developed CMV infections. There was no association between the IE1-specific ELISPOT assay and CMV infection. However, only 15 (31%) of the 48 patients with positive pp65-specific ELISPOT results (>10 spots/2.0 × 105 cells) developed CMV infections, whereas 12 (57%) of the 21 patients with negative pp65-specific ELISPOT results developed CMV infection (P = 0.04). Conclusion Negative pp65-specific ELISPOT assay results before transplantation appear to predict the subsequent development of CMV infections after transplantation in CMV IgG (+) KT recipients. Therefore, risk stratification of CMV IgG (+) recipients using the CMV-specific ELISPOT, together with preventive strategies, may further reduce CMV development.

[1]  Matthew S. Lewis,et al.  Cytomegalovirus pp65 limits dissemination but is dispensable for persistence. , 2014, The Journal of clinical investigation.

[2]  J. Torras,et al.  Pretransplant Immediately Early‐1‐Specific T Cell Responses Provide Protection for CMV Infection After Kidney Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  M. Ison,et al.  Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  A. Humar,et al.  Cytomegalovirus in Solid Organ Transplantation , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  H. Sung,et al.  Diagnostic yield of the cytomegalovirus (CMV) antigenemia assay and clinical features in solid organ transplant recipients and hematopoietic stem cell transplant recipients with CMV pneumonia , 2012, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  J. Orens,et al.  Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients. , 2011, The Journal of infectious diseases.

[7]  N. Khardori.  Rapid Diagnosis of Tuberculous Meningitis by T Cell–Based Assays on Peripheral Blood and Cerebrospinal Fluid Mononuclear Cells , 2010 .

[8]  Eun Jung Lee,et al.  Diagnostic performance of the cytomegalovirus (CMV) antigenemia assay in patients with CMV gastrointestinal disease. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  O. Manuel,et al.  Cell‐Mediated Immunity to Predict Cytomegalovirus Disease in High‐Risk Solid Organ Transplant Recipients , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  F. Kern,et al.  High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. , 2009, Transplant immunology.

[11]  I. Binet,et al.  Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients , 2008, Journal of Translational Medicine.

[12]  R. Hetzer,et al.  Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells , 2005, The Journal of experimental medicine.

[13]  T. Hibi,et al.  Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation , 2000, Bone Marrow Transplantation.